Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer
Titel:
Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer
Auteur:
Martin, Nicolas Isambert, Nicolas Gomez-Roca, Carlos Goeldner, Rainer-Georg Zanetta, Sylvie Sadrolhefazi, Behbood Mont-Serrat, Hélène de Campone, Mario Delord, Jean-Pierre